View Clinical Trial (Medical Research Study)
Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
| City: |
|
Jacksonville |
| State: |
|
Florida |
| Zip Code: |
|
32207 |
| Conditions: |
|
Asthma - Obesity |
| Purpose: |
|
This project will assess the effectiveness of omega-3 fatty acid supplementation in
controlling asthma symptoms among obese asthmatics, and will assess if a person's genes
influence response to treatment (personalized medicine). This project may improve our
ability to treat asthma and our understanding of the link between obesity and asthma.
|
| Study Summary: |
|
Obesity increases the risk for asthma diagnosis in children and adults. With obesity on the
rise, a better understanding of this association may become critically important to public
health. We will determine the impact of fish oil-derived Eicosapentaenoic acid (EPA) and
Docosahexaenoic acid (DHA) on asthma control among obese asthmatics. These omega-3 fatty
acids have been shown to: reduce inflammation important to asthma and improve asthma
outcomes in an inconsistent manner across previous smaller studies - results that are
consistent with a pharmacogenetic influence. There exists evidence that omega-3 fatty acid
response displays a pharmacogenetic response related to ALOX5 genotype. Preliminary data
suggests that obese individuals are at greater risk for possessing this same ALOX5 variant
and thus obese asthmatics may be more responsive to fish oil. We will determine (in a
sub-aim) if there exists an ALOX5 genotype-related response effect with fish oil. This will
be the largest clinical trial of omega-3 fatty acid for the treatment of asthma, and the
first applying pharmacogenetic/nutrigenetic analysis.
|
| Criteria: |
|
Inclusion Criteria:
- age 12-25
- BMI > 30 (age 18-25) or BMI%>95th (age 12-17)
- Physician diagnosis of persistent asthma
- Lung function responsiveness by bronchodilator reversibility or bronchoprovocation
testing
Exclusion Criteria:
- pregnancy
- currently taking LTRA for asthma control
- other serious chronic medical condition
- bleeding diathesis
- severe asthma
|
| NCT ID: |
|
NCT01027143 |
| Primary Contact: |
|
Principal Investigator
Jason E. Lang, M.D.
Nemours Children's Clinic
Jason E. Lang, M.D.
Phone: 904-697-3683
Email: jelang@nemours.org
|
| Backup Contact: |
|
Email: srutledg@nemours.org
Burnese Rutledge, RN
Phone: 904-697-3683
|
| Location Contact: |
|
Jacksonville, Florida 32207
United States
Jason E. Lang, M.D.
Phone: 904-697-3683
Email: jelang@nemours.org
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|